Clinical Trials in Seattle

Showing 3121-3140 of 4,491 trials

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

NCT01953874

The aim of the study is to compare the effects of MV targeted ASV in addition to optimized medical therapy versus optimized medical therapy alone at 6 months in patients with acute decompensated HF. The study will also assess changes in functional parameters, biomarkers, quality of life (QOL), and sleep.

Acute Decompensated Heart FailureSleep Disordered Breathing

ResMed126 participantsStarted Dec 2013

Huntsville, Alabama, United States • Los Angeles, California, United States • Denver, Colorado, United States +12 more locations

TERMINATEDPhase 1< 1 mile

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

NCT02122146

To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Neoplasms

Pfizer31 participantsStarted Aug 2014

Los Angeles, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +7 more locations

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Find Trials by Condition in Seattle

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Lesinurad and Febuxostat Combination Extension Study in Gout

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)

Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Asthma Exacerbation Study

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Contrast Enhanced (CE) Ultrasound and CE Computed Tomography or CE Magnetic Resonance Imaging in Liver Masses

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

Study of Ruxolitinib in Colorectal Cancer Patients

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

NOLAN: Naproxen or Loratadine and Neulasta

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients